Cosmos Health Provides an Update on its Debt Balance and Proforma Interest Expense
Reduced its debt by 78% from $21.2M in 2021 to $4.6M in 2022 and expects interest expense in 2023 to be $0.6M versus $2.2M in 2022.
CHICAGO, IL / ACCESSWIRE / January 17, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced an update regarding its debt balance and proforma interest expense in 2023.
Cosmos Health ended 2022 with long term debt of roughly $4.6M, a reduction of $16.6M, versus the Company's 2021 debt balance of $21.2M. This is a 78% year over year debt reduction, versus the Company's previously announced guidance for a 50% year over year debt reduction by the end of 2022. The substantial reduction in debt was facilitated by the Company's $32.5M registered public offering. As a result of the reduced debt balance, Cosmos expects its interest expense in 2023 to be reduced by 72%, roughly at $0.6M, a decrease of about $1.6M versus the $2.2M interest expense expected in 2022.
Greg Siokas, Chief Executive Officer of Cosmos Health stated, "We are happy to have achieved our goal of strengthening our balance sheet, by substantially reducing our debt. Our new capital structure not only decreases our risk profile, but also lowers our interest expense. Furthermore, our recently strengthened balance sheet allows us the ability to execute on our multi layered growth strategy which is now underway. We continue to enter into strategic agreements with partners which we expect to lead to revenue growth for many years to come."
About Cosmos Health, Inc
Cosmos Health Inc. (Nasdaq:COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Lytham Partners, LLC
SOURCE: Cosmos Health Inc.
View source version on accesswire.com: